Samil Pharmaceutical Co.,Ltd Statistics

Total Valuation

Samil Pharmaceutical Co.,Ltd has a market cap or net worth of KRW 284.59 billion. The enterprise value is 425.13 billion.

Market Cap	284.59B
Enterprise Value	425.13B

Important Dates

The last earnings date was Thursday, November 14, 2024.

Earnings Date	Nov 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Samil Pharmaceutical Co.,Ltd has 21.16 million shares outstanding. The number of shares has decreased by -6.94% in one year.

Current Share Class	n/a
Shares Outstanding	21.16M
Shares Change (YoY)	-6.94%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	23.55%
Owned by Institutions (%)	5.39%
Float	15.28M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.99
PB Ratio	1.59
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 36.36, with an EV/FCF ratio of -54.93.

EV / Earnings	-368.03
EV / Sales	2.02
EV / EBITDA	36.36
EV / EBIT	67.88
EV / FCF	-54.93

Financial Position

The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.82.

Current Ratio	0.74
Quick Ratio	0.35
Debt / Equity	0.82
Debt / EBITDA	12.19
Debt / FCF	-18.42
Interest Coverage	2.38

Financial Efficiency

Return on equity (ROE) is -0.75% and return on invested capital (ROIC) is 1.27%.

Return on Equity (ROE)	-0.75%
Return on Assets (ROA)	1.04%
Return on Capital (ROIC)	1.27%
Revenue Per Employee	359.61M
Profits Per Employee	-1.97M
Employee Count	586
Asset Turnover	0.56
Inventory Turnover	4.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +117.64% in the last 52 weeks. The beta is 0.34, so Samil Pharmaceutical Co.,Ltd's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	+117.64%
50-Day Moving Average	14,785.40
200-Day Moving Average	10,608.30
Relative Strength Index (RSI)	35.12
Average Volume (20 Days)	396,258

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Samil Pharmaceutical Co.,Ltd had revenue of KRW 210.73 billion and -1.16 billion in losses. Loss per share was -74.70.

Revenue	210.73B
Gross Profit	78.79B
Operating Income	6.26B
Pretax Income	2.87B
Net Income	-1.16B
EBITDA	11.69B
EBIT	6.26B
Loss Per Share	-74.70

Full Income Statement

Balance Sheet

The company has 2.01 billion in cash and 142.55 billion in debt, giving a net cash position of -140.54 billion or -6,642.07 per share.

Cash & Cash Equivalents	2.01B
Total Debt	142.55B
Net Cash	-140.54B
Net Cash Per Share	-6,642.07
Equity (Book Value)	174.36B
Book Value Per Share	8,433.37
Working Capital	-29.59B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.33 billion and capital expenditures -23.07 billion, giving a free cash flow of -7.74 billion.

Operating Cash Flow	15.33B
Capital Expenditures	-23.07B
Free Cash Flow	-7.74B
FCF Per Share	-365.78

Full Cash Flow Statement

Margins

Gross margin is 37.39%, with operating and profit margins of 2.97% and -0.55%.

Gross Margin	37.39%
Operating Margin	2.97%
Pretax Margin	1.36%
Profit Margin	-0.55%
EBITDA Margin	5.55%
EBIT Margin	2.97%
FCF Margin	-3.67%

Dividends & Yields

Samil Pharmaceutical Co.,Ltd does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	6.94%
Shareholder Yield	6.94%
Earnings Yield	-0.56%
FCF Yield	-2.72%

Dividend Details

Stock Splits

The last stock split was on March 24, 2023. It was a forward split with a ratio of 1.1.

Last Split Date	Mar 24, 2023
Split Type	Forward
Split Ratio	1.1

Scores

Samil Pharmaceutical Co.,Ltd has an Altman Z-Score of 0.99. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.99
Piotroski F-Score	n/a